Literature DB >> 30816448

Tanshinone IIA inhibits lipopolysaccharide‑induced inflammatory responses through the TLR4/TAK1/NF‑κB signaling pathway in vascular smooth muscle cells.

Zhe Meng1, Chun-Ying Si2, Shuai Teng1, Xin-Hui Yu3, Hai-Yu Li1.   

Abstract

To aim of the present study was to determine whether Tanshinone IIA (Tan IIA) inhibits lipopolysaccharide (LPS)‑induced inflammation in vascular smooth muscle cells (VSMCs) from rats and elucidate the underlying molecular mechanism. VSMCs were primarily cultured and then treated with LPS (1 µg/l) and Tan IIA (25, 50 and 100 µmol/l) for 24 h. Monocyte chemoattractant protein (MCP)‑1, interleukin (IL)‑6 and tumor necrosis factor (TNF)‑α levels were detected by ELISA and reverse transcription‑quantitative polymerase chain reaction. Nitric oxide (NO) production was measured using the Griess reaction. The expression of Toll‑like receptor 4 (TLR4), nuclear factor (NF)‑κB (p65), and inducible NO synthase (iNOS), and the phosphorylation of transforming growth factor‑β‑activated kinase 1 (TAK1) were detected by western blot analysis. Tan IIA inhibited the LPS‑induced expression of MCP‑1, IL‑6, and TNF‑α in a concentration‑dependent manner and inhibited iNOS‑mediated NO production. In addition, Tan IIA suppressed the expression of TLR4, the phosphorylation of TAK1, and the nuclear translocation of NF‑κB (p65). The anti‑TLR4 antibody and TAK1 inhibitor 5Z‑7‑oxozeaenol partially attenuated the LPS‑induced expression of proinflammatory cytokines. In conclusion, Tan IIA inhibits LPS‑induced inflammatory responses in VSMCs in vitro through the partial suppression of the TLR4/TAK1/NF‑κB signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30816448     DOI: 10.3892/ijmm.2019.4100

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

Review 1.  TAK1 signaling is a potential therapeutic target for pathological angiogenesis.

Authors:  Linxin Zhu; Suraj Lama; Jiang-Hui Wang; Guei-Sheung Liu; Leilei Tu; Gregory J Dusting
Journal:  Angiogenesis       Date:  2021-05-10       Impact factor: 10.658

2.  Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway.

Authors:  Rui Wang; Zhilin Luo; Hong Zhang; Tianhu Wang
Journal:  Onco Targets Ther       Date:  2019-11-07       Impact factor: 4.147

3.  Tanshinone IIA attenuates renal injury during hypothermic preservation via the MEK/ERK1/2/GSK-3β pathway.

Authors:  Linhao Xu; Yizhou Xu; Zhoujing Zhu; Huiquan Gu; Chaofeng Chen; Jian Chen
Journal:  BMC Complement Med Ther       Date:  2021-10-08

4.  Carbon Monoxide-Releasing Molecule-2 Ameliorates Particulate Matter-Induced Aorta Inflammation via Toll-Like Receptor/NADPH Oxidase/ROS/NF-κB/IL-6 Inhibition.

Authors:  Thi Thuy Tien Vo; Chien-Yi Hsu; Yinshen Wee; Yuh-Lien Chen; Hsin-Chung Cheng; Ching-Zong Wu; Wei-Ning Lin; I-Ta Lee
Journal:  Oxid Med Cell Longev       Date:  2021-07-13       Impact factor: 6.543

Review 5.  Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases.

Authors:  Rui Guo; Lan Li; Jing Su; Sheng Li; Sophia Esi Duncan; Zhihao Liu; Guanwei Fan
Journal:  Drug Des Devel Ther       Date:  2020-11-05       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.